1. Pak CS, Lee J, Lee H, Jeong J, Kim EH, Jeong J, Choi H, Kim B, Oh S, Kim I, Heo CY. A phase III, randomized, double-blind, matched-pairs, active-controlled clinical trial and preclinical animal study to compare the durability, efficacy and safety between polynucleotide filler and hyaluronic acid filler in the correction of crow's feet: a new concept of regenerative filler. J Korean Med Sci 2014;29 Suppl 3:S201-9.

2. 2014 Complete Plastic Surgery Statistic Report. Ameircan Society of Plastic Surgeons. Available from:

3. Carruthers J, Carruthers A, Humphrey S. Introduction to fillers. Plast Reconstr Surg 2015;136 Suppl 5:S120-31.

4. Requena L, Requena C, Christensen L, Zimmermann US, Kutzner H, Cerroni L. Adverse reactions to injectable soft tissue fillers. J Am Acad Dermatol 2011;64:1-34.

5. Christensen L, Breiting V, Janssen M, Vuust J, Hogdall E. Adverse reactions to injectable soft tissue permanent fillers. Aesthetic Plast Surg 2005;29:34-48.

6. De Boulle K. Management of complications after implantation of fillers. J Cosmet Dermatol 2004;3:2-15.

7. Bertossi D, Sbarbati A, Cerini R, Barillari M, Favero V, Picozzi V, Ruzzenente O, Salvagno G, Guidi GC, Nocini P. Hyaluronic acid: in vitro and in vivo analysis, biochemical properties and histological and morphological evaluation of injected filler. Eur J Dermatol 2013;23:449-55.

8. Wang F, Garza LA, Kang S, Varani J, Orringer JS, Fisher GJ, Voorhees JJ. In vivo stimulation of a de novo collagen production caused by cross-linked hyaluronic acid dermal filler injections in photodamaged human skin. Arch Dermatol 2007;143:155-63.

9. Turlier V, Delalleau A, Casas C, Rouquier A, Bianchi P, Alvarez S, Josse G, Briant A, Dahan S, Saint-Martory C, Theunis J, Bensafi-Benaouda A, Degouy A, Schmitt AM, Redoulès D. Association between collagen production and mechanical stretching in dermal extracellular matrix: in vivo effect of cross-linked hyaluronic acid filler. A randomised, placebo-controlled study. J Dermatol Sci 2013;69:187-94.

10. Watson W, Kaye RL, Klein A, Stegman S. Collagen: a clinical overview. Cutis 1983;31:543-6.

11. Klein AW, Rish DC. Dermatology: bovine injectable collagen. West J Med 1985;143:231.

12. Knapp TR, Kaplan EN, Daniels JR. Injectable collagen for soft tissue augmentation. Plast Reconstr Surg 1977;60:389-405.

13. Stegman SJ, Chu S, Bensch K, Amstrong R. A light and electron microscopic evaluation of Zyderm collagen and Zyplast implants in aging human facial skin: a pilot study. Arch Dermatol 1987;123:1644-9.

14. Douglas RS, Donsoff I, Cook T, Shorr N. Collagen fillers in facial aesthetic surgery. Facial Plast Surg 2004;20:117-23.

15. Mullins RJ, Richards C, Walker T. Allergic reaction to oral, surgical and topical bovine collagen. Anaphylactic risk for surgeons. Aust N Z J Ophthalmol 1996;24:257-60.

16. Siegle RJ, McCoy JP, Schade W, Swanson NA. Intradermal implantation of bovine collagen. humoral immune responses associated with clinical reactions. Arch Dermatol 1984;120:183-7.

17. Sclafani A, Romo T, Jacono AA, McCormick SA, Cocker R, Parker A. Evaluation of acellular dermal graft in sheet (Alloderm) and injectable (micronized Alloderm) forms for soft tissue augmentation: clinical observations and histologic findings. Arch Facial Plast Surg 2000;2:130-6.

18. Fagien S. Facial soft-tissue augmentation with injectable autologous and allogenic human tissue collagen matrix (autologen and dermalogen). Plast Reconstr Surg 2000;105:362-73.

19. Moody BR, Sengelmann RD. Self-limited adverse reaction to human-derived collagen injectable product. Dermatol Surg 2000;26:936-8.

20. Wise JB, Greco T. Injectable treatments for the aging face. Facial Plast Surg 2006;22:140-6.

21. Lupo MP. Hyaluronic acid fillers in facial rejuvenation. Semin Cutan Med Surg 2006;25:122-6.

22. Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T, Miyake K, Freudenberg M, Galanos C, Simon JC. Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 2002;195:99-111.

23. Mansouri Y, Goldenberg G. Update on hyaluronic acid fillers for facial rejuvenation. Cutis 2015;96:85-8.

24. Turlier V, Delalleau A, Casas C, Rouquier A, Bianchi P, Alvarez S, Josse G, Briant A, Dahan S, Saint-Martory C, Theunis J, Bensafi-Benaouda A, Degouy A, Schmitt AM, Redoulès D. Association between collagen production and mechanical stretching in dermal extracellular matrix: in vivo effect of cross-linked hyaluronic acid filler. A randomised, placebo-controlled study. J Dermatol Sci 2013;69:187-94.

25. Quan T, Wang F, Shao Y, Rittié L, Xia W, Orringer JS, Voorhees JJ, Fisher GJ. Enhancing structural support of the dermal microenvironment activates fibroblasts, endothelial cells, and keratinocytes in aged human skin in vivo. J Invest Dermatol 2013;133:658-67.

26. Duranti F, Salti G, Bovani B, Calandra M, Rosati ML. Injectable hyaluronic acid gel for soft tissue augmentation. A clinical and histological study. Dermatol Surg 1998;24:1317-25.

27. Narins RS, Brandt F, Leyden J, Lorenc ZP, Rubin M, Smith S. A randomized, double-blind, multicenter comparison of the efficacy and tolerability of Restylane versus Zyplast for the correction of nasolabial folds. Dermatol Surg 2003;29:588-95.

28. Palm MD. Filler frontier: what's new and heading West to the US market. Semin Cutan Med Surg 2014;33:157-63.

29. Brandt FS, Cazzaniga A. Hyaluronic acid gel fillers in the management of facial aging. Clin Interv Aging 2008;3:153-9.

30. Mansouri Y, Goldenberg G. Update on hyaluronic acid fillers for facial rejuvenation. Cuti 2015;96:85-8.

31. Pollack SV. Some new injectable dermal filler materials: Hylaform, Restylane and Artecoll. J Cutan Med Surg 1999;Suppl 4:S27-35.

32. Rongioletti F, Cattarini G, Sottofattori E, Rebora A. Granulomatous reaction after intradermal injections of hyaluronic acid gel. Arch Dermatol 2003;139:815-6.

33. Shafir R, Amir A, Gur E. Long-term complications of facial injections with Restylane (injectable hyaluronic acid). Plast Reconstr Surg 2000;106:1215-6.

34. Dal Sacco D, Cozzani E, Parody A, Rebora A. Scar sarcoidosis after hyaluronic acid injection. Int J Dermatol 2005;44:411-2.

35. Descamps V, Landry J, Frances C, Marinho E, Ratziu V, Chosidow O. Facial cosmetic filler injections as possible target for systemic sarcoidosis in patients treated with interferon for chronic hepatitis C: two cases. Dermatol 2008;217:81-4.

36. Schanz S, Schipper W, Ulmer A, Rassner G, Fierlbeck G. Arterial embolization caused by injection of hyaluronic acid (Restylane). Br J Dermatol 2002;146:928-9.

37. Grossman KL. Hyaluronic acid gel fillers: hypersensitivity reactions. Aesthet Surg J 2005;25:403-5.

38. Leonard JM, Lawrence N, Narin RS. Angioedema acute hypersensitivity reaction to injectable hyaluronic acid. Dermatol Surg 2005;31:577-9.

39. Schierle CF, Casas LA. Nonsurgical rejuvenation of the aging face with injectable poly-L-lactic acid for storation of soft tissue volume. Aesthet Surg J 2011;31:95-109.

40. Ladewig K, Abberton K, Andrea J O'Connor. Designing in vivo bioreactors for soft tissue engineering. J Biomater Tissue Engineering 2012;2:1-13.

41. Gogolewski S, Jovanovic M, Perren SM, Dilon JG, Hughes MK. Tissue response and in vivo degradation of selected poly-hydroxyacids: polylactides (PLA), poly(3-hydroxybutyrate) (PHB) and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHB/VA). J Biomed Mater Res 1993;27:1135-48.

42. Lam SM, Azizzadeh B, Graivier M. Injectable poly-L-lactic acid (Sculptra): technical considerations in soft-tissue contouring. Plast Reconstr Surg 2006;118:S55-63.

43. Vleggaar D. Facial volumetric correction with injectable poly-L-lactic acid. Dermatol Surg 2005;31:1511-7.

44. Vleggaar D, Bauer U. Facial enhancement and the European experience with Sculptra (poly-L-lactic acid). J Drugs Dermatol 2004;3:542-7.

45. Athanasiou KA, Niederauer GG, Agrawal CM, Landsman AS. Applications of biodegradable lactides and glycolides in podiatry. Clin Podiatr Med Surg 1995;12:475-95.

46. Spenlehauer G, Vert M, Benoit JP, Boddaert A. In vitro and in vivo degradation of poly(D, L-lactide/glycolide) acid microspheres made by solvent evaporation method. Biomater 1989;10:557-63.

47. Vleggaar D. Soft-tissue augmentation and the role of poly-L-lactic acid. Plast Reconstr Surg 2006;118:S46-54.

48. Valantin MA, Aubron-Olivier C, Ghosn J, Laglenne E, Pauchard M, Schoen H, Bousquet R, Katz P, Costagliola D, Katama C. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study. AIDS 2003;17:2471-7.

49. Lemperle G, Rullan PP, Gauthier-Hazan N. Avoiding and treating dermal filler complications. Plast Reconstr Surg 2006;118:S92-107.

50. Alijotas-Reig J, Fernández-Figueras MT, Puig L. Inflammatory, immune-mediated adverse reactions related to soft tissue dermal fillers. Semin Arthritis Rheum 2013;43:241-58.

51. Fan M, Liao J, Guo G, Ding Q, Yang Y, Luo F, Qian Z. Dexamethasone-loaded poly (D,L-lactic acid) microspheres/poly (ethylene glycol) = poly (epsilon-caprolactone) – poly (ethylene glycol) micelles composite for skin augmentation. J Biomed Nanotechnol 2014;10:592-602.

52. Lafaurie M, Dolivo M, Porcher R, Rudant J, Madelaine I, Molina JM. Treatment of facial lipoatrophy with intradermal injections of polylactic acid in HIV-infected patients. J Acquir Immune Defic Syndr 2005;38:393-8.

53. Tzikas TL. Evaluation of the radiance FN soft tissue filler for facial soft tissue augmentation. Arch Facial Plast Surg 2004;6:234-9.

54. Marmur ES, Phelps R, Goldberg DJ. Clinical, histologic and electron microscopic findings after injection of a calcium hydroxylapatite filler. J Cosmet Laser Ther 2004;6:223-6.

55. Broder KW, Cohen SR. An overview of permanent and semipermanent fillers. Plast Reconstr Surg 2006;118:7S-14S.

56. Silvers SL, Eviatar JA, Echavez MI, Pappas AL. Prospective, open-label, 18-month trial of calcium hydroxylapatite (Rad-iesse) for facial soft-tissue augmentation in patient with human immunodeficiency virus-associated lipoatrophy: one-year durability. Plast Reconstr Surg 2006;118:S34-45.

57. Sklar JA, White SM. Radiance FN: a new soft tissue filler. Dermatol Surg 2004;30:764-8.

58. Jansen DA, Graivier MH. Evaluation of calcium hydroxylapatite based implant (Radiesse) for facial soft-tissue augmentation. Plast Reconstr Surg 2006;118:S22-30.

59. Ahn MS. Calcium hydroxylapatite: Radiesse. Facial Plast Surg Clin North Am 2007;15:85-90.

60. Duffy DM. Complications of fillers. Overview. Dermatol Surg 2005;31:1626-33.

61. Beer KR. Radiesse nodule of the lips from a distant injection site: report of a case and consideration of etiology and management. J Drugs Dermatol 2007;6:846-7.

62. Kim JA, Van Abel D. Neocollagenesis in human tissue injected with a polycaprolactone-based dermal filler. J Cosmet Laser Ther 2015;17:99-101.

63. Moers-Carpi MM, Sherwood S. Polycaprolactone for the correction of nasolabial folds: a 24-month, rospective, randomized, controlled clinical trial. Dermatol Surg 2013;39:457-63.

64. Figueiredo VM. A five-patient prospective pilot study of a polycaprolactone based dermal filler for hand rejuvenation. J Cosmet Dermatol 2013;12:73-7.

65. Nicolau PJ, Marijnissen-Hofsté J. Neocollagenesis after injection of a polycaprolactone based derma filler in a rabbit. Eur J Aesth Med Dermatol 2013;3:19-26.

66. Leonardis M, Palange A. New-generation filler based on cross-linked carboxymethylcellulose: study of 350 patients with 3-year follow-up. Clin Interv Aging 2015;10:147-55.

67. Leonardis M, Palange A, Dornelles RF, Hund F. Use of cross-linked carboxymethyl cellulose for soft-tissue augmentation: preliminary clinical studies. Clin Interv Aging 2010;5:317-22.

68. Neuber F. Fettransplantation. Chir Kongr Verhandl Dsch Gesellch Chir 1893;22:66.

69. Cervelli V, Palla L, Pascali M, De Angelis B, Curcio BC, Gentile P. Autologous platelet-rich plasma mixed with purified fat graft in aesthetic plastic surgery. Aesthetic Plast Surg 2009;33:716-21.

70. Sterodimas A, De Faria J, Nicaretta B, Papadopoulos O, Papalambros E, Illouz YG. Cell-assisted lipotransfer. Aesthet Surg J 2010;30:78-81.

71. Ersek RA. Transplantation of purified autologous fat: a 3-year follow-up is disappointing. Plast Reconstr Surg 1991;87:219-27.

72. Coleman SR. Long-term survival of fat transplants: controlled demonstrations. Aesthetic Plast Surg 1995;19:421-5.

73. Fulton JE, Suarez M, Silverton K, Barnes T. Small volume fat transfer. Dermatol Surg 1998;24:857-65.

74. Fournier PF. Fat grafting: my technique. Dermatol Surg 2000;26:1117-28.

75. Kanchwala SK, Bucky LP. Facial fat grafting: the search for predictable results. Facial Plast Surg 2003;19:137-46.

76. Cheng JT, Perkins SW, Hamilton MM. Collagen and injectable fillers. Otolaryngol Clin North Am 2002;35:73-85.

77. Carruthers JD, Fagien S, Rohrich RJ, Weinkle S, Carruthers A. Blindness caused by cosmetic filler injection: a review of cause and therapy. Plast Reconstr Surg 2014;134:1197-201.

78. Hong DK, Seo YJ, Lee JH, Im M. Sudden visual loss and multiple cerebral infarction after autologous fat injection into the glabella. Dermatol Surg 2014;40:485-7.

79. Yamauchi PS. Emerging permanent filler technologies: focus on aquamid. Clin Cosmet Investig Dermatol 2014;7:261-6.

80. Peters W, Fornasier V. Complications from injectable materials used for breast augmentation. Can J Plast Surg 2009;17:89-96.

81. Altmeyer MD, Anderson LL, Wang AR. Silicone migration and granuloma formation. J Cosmet Dermatol 2009;8:92-7.

82. Schwartzfarb EM, Hametti JM, Romanelli P, Ricotti C. Foreig body granuloma formation secondary to silicone injection. Dermatol Online J 2008;14:20.

83. Ficarra G, Mosqueda-Taylor A, Carlos R. Silicone granuloma of the facial tissues: a report of seven cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;94:65-73.

84. Schmid A, Tzur A, Leshko L, Krieger BP. Silicone embolism syndrome: a case report, review of the literature, and comparison with fat embolism syndrome. Chest 2005;127:2276-81.

85. Vent J, Lemperle G. Prevention and treatment of complications after polymethylmethacrylate-microspheres injections. Facial Plast Surg 2014;30:628-34.

86. Lemperle G, Nacul AM, Fortes FB. Can injection of PMMA-microspheres cause hypercalcemia? Clin Cases Miner Bone Metab 2015;12:82-3.

87. Bachmann F, Erdmann R, Hartmann V, Becker-Wegerich P, Wiest L, Rzany B. Adverse reactions caused by consecutive injections of different fillers in the same facial region: risk assessment based on the results from the injectable filler safety study. J Eur Acad Dermatol Venereol 2011;25:902-12.

88. Limongi RM, Tao J, Borba A, Pereira F, Pimentel AR, Akaishi P, Velasco E Cruz AA. Complications and management of polymethylmethacrylate (PMMA) injections to the midface. Aesthet Surg J 2016;36:132-5.

89. Christensen LH, Breiting VB, Aasted A, Jørgensen A, Kebuladze I. Long-term effects of polyacrylamide hydrogel on human breast tissue. Plast Reconstr Surg 2003;111:1883-90.

90. Breiting V, Aasted A, Jørgensen A, Opitz P, Rosetzsky A. A study on patients treated with polyacrylamide hydrogel injection for facial corrections. Aesthetic Plast Surg 2004;28:45-53.

91. Von Buelow S, Von Heimburg D, Pallua N. Efficacy and safety of polyacrylamide hydrogel for facial soft-tissue augmentation. Plast Reconstr Surg 2005;116:1137-46.

92. Von Buelow S, Pallua N. Efficacy and safety of polyacrylamide hydrogel for facial soft-tissue augmentation in a 2-year follow-up: a prospective multicenter study for evaluation of safety and aesthetic results in 101 patients. Plast Reconstr Surg 2006;118:S85-91.

93. De Santis G, Jacob V, Baccarani A, Pedone A, Pinelli M, Spaggiari A, Guaraldi G. Polyacrylamide hydrogel injection in the management of human immunodeficiency virus-related facial lipoatrophy: a 2-year clinical experience. Plast Reconstr Surg 2008;121:644-53.

94. Negredo E, Puig J, Aldea D, Medina M, Estany C, Pérez-Alvarez N, Rodríguez-Fumaz C, Mu-oz-Moreno JA, Higueras C, Gonzalez-Mestre V, Clotet B. Four-year safety with polyacrylamide hydrogel to correct antiretroviral-related facial lipoatrophy. AIDS Res Hum Retroviruses 2009;25:451-5.

95. Wolters M, Lampe H. Prospective multicenter study for evaluation of safety, efficacy, and esthetic results of crosslinked polyacrylamide hydrogel in 81 patients. Dermatol Surg 2009;35 Suppl 1:338-43.

96. Mole B, Gillaizeau F, Carbonnel E, Pierre I, Brazille P, Grataloup C, Mercier S, Duracinsky M, Weiss L, Piketty C. Polyacrylamide hydrogel injection in the management of human immunodeficiency virus-related facial lipoatrophy: results of the LIPOPHILL open-label study. AIDS Res Hum Retroviruses 2012;28:251-8.

97. Lafaurie M, Dolivo M, Girard PM, May T, Bouchaud O, Carbonnel E, Madelaine I, Loze B, Porcher R, Molina JM; ANRS 132 SMILE study group. Polylactic acid vs. polyacrylamide hydrogel for treatment of facial lipoatrophy: a randomized controlled trial [Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS) 132 SMILE]. HIV Med 2013;14:410-20.

98. Narins RS, Coleman WP 3rd, Rohrich R, Monheit G, Glogau R, Brandt F, Bruce S, Colen L, Dayan S, Jackson I, Maas C, Rivkin A, Sclafani A, Spivak JC. 12-Month controlled study in the United States of the safety and efficacy of a permanent 2.5% polyacrylamide hydrogel softtissue filler. Dermatol Surg 2010;36 Suppl 3:1819-29.

99. Fernández-Cossío S, Casta-o-Oreja MT. Biocompatibility of two novel dermal fillers: histological evaluation of implants of a hyaluronic acid filler and a polyacrylamide filler. Plast Reconstr Surg 2006;117:1789-96.

100. Christensen L, Breiting V, Bjarnsholt T, Eickhardt S, Høgdall E, Janssen M, Pallua N, Zaat SA. Bacterial infection as a likely cause of adverse reactions to polyacrylamide hydrogel fillers in cosmetic surgery. Clin Infect Dis 2013;56:1438-44.

101. Nygart JF, Nygart VA, Borggren M, Tvede M. Effect of prophylactic antibiotics on polyacrylamide gel safety in facial augmentation. J Drugs Dermatol 2014;13:571-3.

102. Ersek RA, Beisang AA, 3rd. Bioplastique: a new texture copolymer microparticle promises permanence in soft tissue augmentation. Plast Reconstr Surg 1991;33:693-702.

103. Rudolph CM, Soyer HP, Schuller-Petrovic S, Kerl H. Bioplastiquegranulom. Hautarzt 1997;48:749-52.

104. Hoffmann C, Schuller-Petrovic S, Soyer HP, Kerl H. Adverse reactions after cosmetic augmentation with permanent biologically inert implant materials. J Am Acad Dermatol 1999;40:100-2.

105. Rudolph CM, Soyer HP, Schuller-Petrovic S, Kerl H. Foreign body granulomas due to injectable aesthetic microimplants. Am J Surg Pathol 1999;23:113-7.

106. Margolis DM. Treatment for lipoatrophy: facing the real costs. AIDS 2007;21:1819-20.

107. Nelson L, Stewart KJ. Experience in the treatment of HIV-associated lipodystrophy. J Plast Reconstr Aesthet Surg 2008;61:366-71.

108. Karim RB, De Lint CA, Van Galen SR, Van Rozelaar L, Nieuwkerk PT, Askarizadeh E, Hage JJ. Long-term effect of polyalkylimide gel injections on severity of facial lipoatrophy and quality of life of HIV-positive patients. Aesthetic Plast Surg 2008;32:873-8.

109. Mallewa JE, Wilkins E, Vilar J, Mallewa M, Doran D, Back D, Pirmohamed M. HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options. J Antimicrob Chemother 2008;62:648-60.

110. Hönig J. Cheek augmentation with Bio-Alcamid in facial lipoatrophy in HIV seropositive patients. J Craniofac Surg 2008;19:1085-8.

Plastic and Aesthetic Research
ISSN 2349-6150 (Online)   2347-9264 (Print)


All published articles are preserved here permanently:


All published articles are preserved here permanently: